Nasdaq:US$40.98 (-0.83) | HKEX:HK$70.85 (-6.75) | AIM:£5.92 (+0.14)
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2009-11-05

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans